
Sign up to save your podcasts
Or


Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.
Read the full article:
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv
By The Lancet GroupEdouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.
Read the full article:
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv

137 Listeners

320 Listeners

497 Listeners

68 Listeners

7 Listeners

18 Listeners

3,350 Listeners

1,146 Listeners

193 Listeners

93 Listeners

513 Listeners

247 Listeners

21 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

1 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

12 Listeners

17 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners